In addition, the tumor levels of G-MDSCs were significantly reduced, and activated CD8+ T cells were significantly increased in the combination therapy groups, while no changes in peripheral blood lymphoid and myeloid subsets were observed (Figures S3B, C and S4B, C). The gene discussed is CD8A; the disease is neoplasm.